Sertraline for social phobia

A double-blind, placebo-controlled crossover study

David J Katzelnick, Kenneth A. Kobak, John H. Greist, James W. Jefferson, Julia M. Mantle, Ronald C. Serlin

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

Objective: The authors examined the efficacy of sertraline in the treatment of social phobia. Method: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo. Results: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer. Conclusions: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.

Original languageEnglish (US)
Pages (from-to)1368-1371
Number of pages4
JournalAmerican Journal of Psychiatry
Volume152
Issue number9
StatePublished - Sep 1995
Externally publishedYes

Fingerprint

Sertraline
Cross-Over Studies
Placebos
Anxiety
Double-Blind Method
Outpatients
Social Phobia
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Katzelnick, D. J., Kobak, K. A., Greist, J. H., Jefferson, J. W., Mantle, J. M., & Serlin, R. C. (1995). Sertraline for social phobia: A double-blind, placebo-controlled crossover study. American Journal of Psychiatry, 152(9), 1368-1371.

Sertraline for social phobia : A double-blind, placebo-controlled crossover study. / Katzelnick, David J; Kobak, Kenneth A.; Greist, John H.; Jefferson, James W.; Mantle, Julia M.; Serlin, Ronald C.

In: American Journal of Psychiatry, Vol. 152, No. 9, 09.1995, p. 1368-1371.

Research output: Contribution to journalArticle

Katzelnick, DJ, Kobak, KA, Greist, JH, Jefferson, JW, Mantle, JM & Serlin, RC 1995, 'Sertraline for social phobia: A double-blind, placebo-controlled crossover study', American Journal of Psychiatry, vol. 152, no. 9, pp. 1368-1371.
Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: A double-blind, placebo-controlled crossover study. American Journal of Psychiatry. 1995 Sep;152(9):1368-1371.
Katzelnick, David J ; Kobak, Kenneth A. ; Greist, John H. ; Jefferson, James W. ; Mantle, Julia M. ; Serlin, Ronald C. / Sertraline for social phobia : A double-blind, placebo-controlled crossover study. In: American Journal of Psychiatry. 1995 ; Vol. 152, No. 9. pp. 1368-1371.
@article{db37e791249542be80efee05b35591a9,
title = "Sertraline for social phobia: A double-blind, placebo-controlled crossover study",
abstract = "Objective: The authors examined the efficacy of sertraline in the treatment of social phobia. Method: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo. Results: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer. Conclusions: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.",
author = "Katzelnick, {David J} and Kobak, {Kenneth A.} and Greist, {John H.} and Jefferson, {James W.} and Mantle, {Julia M.} and Serlin, {Ronald C.}",
year = "1995",
month = "9",
language = "English (US)",
volume = "152",
pages = "1368--1371",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "9",

}

TY - JOUR

T1 - Sertraline for social phobia

T2 - A double-blind, placebo-controlled crossover study

AU - Katzelnick, David J

AU - Kobak, Kenneth A.

AU - Greist, John H.

AU - Jefferson, James W.

AU - Mantle, Julia M.

AU - Serlin, Ronald C.

PY - 1995/9

Y1 - 1995/9

N2 - Objective: The authors examined the efficacy of sertraline in the treatment of social phobia. Method: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo. Results: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer. Conclusions: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.

AB - Objective: The authors examined the efficacy of sertraline in the treatment of social phobia. Method: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo. Results: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer. Conclusions: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.

UR - http://www.scopus.com/inward/record.url?scp=0029094582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029094582&partnerID=8YFLogxK

M3 - Article

VL - 152

SP - 1368

EP - 1371

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 9

ER -